Skin and Soft Tissue Infections

184 Skin and Soft Tissue Infections





Community-Acquired Methicillin-Resistant Staphylococcus Aureus


Since the late 1990s, an epidemic of skin and soft tissue infections has been caused by community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Currently in the United States, CA-MRSA is the most common cause of skin and soft tissue infection in patients presenting to emergency departments. Patients who develop these infections have been previously healthy, and most have not been exposed to health care settings or prior antibiotic therapy.1


CA-MRSA is distinguished from hospital-acquired MRSA (HA-MRSA) not only by the location of acquisition, but also by the type of infection produced. HA-MRSA causes wound infections, sepsis, endocarditis, and metastatic infections, but CA-MRSA causes predominantly purulent skin infections. HA-MRSA rarely carries the Panton-Valentine leukocidin that is believed to be a potent virulence factor found in most CA-MRSA strains. In addition, HA-MRSA is generally resistant to many antibiotics, whereas CA-MRSA tends to be resistant predominantly to β-lactam agents but remains susceptible to many other antibiotics, such as trimethoprim-sulfamethoxazole and the tetracyclines. Unfortunately, the designation of these staphylococcal strains based on the site of acquisition has led to confusion now that newly developed CA-MRSA infections have been increasingly identified within hospitals.


In 2011, the Infectious Disease Society of America released its long-anticipated first clinical guidelines for the treatment of MRSA infections, including CA-MRSA, in adults and children.1 The panel of experts provided an evidence-based framework for the clinical evaluation and treatment of skin and soft tissue infections and more invasive infections such as bacteremia and pneumonia.



Superficial Skin Infections





Cellulitis


Cellulitis results from bacterial infection of the dermis and the subcutaneous fat. Infection may arise following the entry of bacteria into the dermis through small breaks in the skin, larger wounds, or preexisting dermatitis. The infection may be limited to a small patch, or it may spread to include extensive areas of skin. Cellulitis is manifested by erythematous, warm, tender regions of skin that frequently spread. Lymphangitis and lymphadenitis may be present. Fever, chills, and malaise are common associated symptoms.


The pathogens of cellulitis are rarely identified in any particular patient, but they are thought to be primarily S. pyogenes (less commonly, other β-hemolytic streptococci such as groups B, C and G) and S. aureus. Culture of material aspirated from the involved skin is not routinely performed because of the invasive nature of the procedure and the low diagnostic yield. Blood cultures are of little value; only approximately 2% to 5% of these cultures yield results. A newer distinction has been proposed between nonpurulent cellulitis, which is believed to be more likely caused by Streptococcus species, and cellulitis that is associated with purulence and is probably caused by S. aureus. (See the later discussion of purulent skin infections.)


Patients with mild cases of nonpurulent cellulitis may be treated on an outpatient basis with an antibiotic effective against Streptococcus species such as cephalexin or dicloxacillin. The precise length of therapy is determined by the patient’s response to therapy. A 5- to 10-day course of antibiotics is recommended. Empiric coverage for CA-MRSA should be reserved for patients who do not respond to β-lactam agents.


In patients with cellulitis who require hospital admission (e.g., those with extensive disease or underlying immunocompromises those who appear toxic), blood cultures are often obtained. Although the diagnostic yield of blood cultures is quite low, these cultures may provide useful information for patients who are significantly ill. Radiography may provide valuable information about patients with significant cellulitis, in particular to establish the presence of gas or foreign bodies. Patients with nonpurulent cellulitis who require admission may be treated with intravenous antibiotics, such as oxacillin, nafcillin, or cefazolin. For patients allergic to penicillin, azithromycin or levofloxacin may be substituted. Empiric coverage for CA-MRSA may be reserved for patients who do not improve during β-lactam therapy.



Purulent Skin Infections


Small, superficial pustular infections arising from the hair follicle are usually caused by S. aureus and are referred to as folliculitis. The lesions of folliculitis tend to be approximately 2 to 5 mm in diameter, they are isolated to the epidermis, and they generally produce pruritus rather than pain. Treatment consists of warm, moist compresses and topical antibiotic ointment, such as mupirocin. If systemic therapy is desired (because of a lack of response to topical therapy, extensive infection, or the presence of underlying immunocompromising medical condition), an agent active against CA-MRSA is recommended (Table 184.1).


Table 184.1 Antibiotics for Community-Acquired Methicillin-Resistant Staphylococcus aureus Skin Infections









DEGREE OF INFECTION ANTIBIOTIC REGIMEN
Mild
Get Clinical Tree app for offline access